- Home
- OCUL
as of 02-11-2026 3:46pm EST
$9.11
+$0.08
+0.83%
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 2.2B | IPO Year: | 2014 |
| Target Price: | $22.56 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.79 - $16.44 | Next Earning Date: | 02-05-2026 |
| Revenue: | $51,951,000 | Revenue Growth: | -18.47% |
| Revenue Growth (this year): | 20.43% | Revenue Growth (next year): | 79.81% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -216893000.0 | FCF Growth: | N/A |
AI-Powered OCUL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.58%
76.58%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
Notman Donald
Sell
Chief Operating Officer
OCUL Feb 4, 2026
Avg Cost/Share
$8.54
Shares
6,035
Total Value
$51,538.90
Owned After
377,802
SEC Form 4
Notman Donald
Sell
Chief Operating Officer
OCUL Feb 2, 2026
Avg Cost/Share
$9.14
Shares
5,455
Total Value
$49,858.70
Owned After
377,802
SEC Form 4
Nayak Sanjay
Sell
Chief Strategy Officer
OCUL Nov 24, 2025
Avg Cost/Share
$12.04
Shares
1,878
Total Value
$22,611.12
Owned After
277,860
SEC Form 4
Dugel Pravin
Sell
See Remarks
OCUL Nov 24, 2025
Avg Cost/Share
$12.04
Shares
19,530
Total Value
$235,141.20
Owned After
3,157,960
SEC Form 4
Kaiser Peter
Sell
Chief Development Officer
OCUL Nov 24, 2025
Avg Cost/Share
$12.02
Shares
3,007
Total Value
$36,144.14
Owned After
191,433
SEC Form 4
Heier Jeffrey S.
Sell
Chief Scientific Officer
OCUL Nov 24, 2025
Avg Cost/Share
$12.04
Shares
3,469
Total Value
$41,766.76
Owned After
245,940
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Notman Donald | OCUL | Chief Operating Officer | Feb 4, 2026 | Sell | $8.54 | 6,035 | $51,538.90 | 377,802 | |
| Notman Donald | OCUL | Chief Operating Officer | Feb 2, 2026 | Sell | $9.14 | 5,455 | $49,858.70 | 377,802 | |
| Nayak Sanjay | OCUL | Chief Strategy Officer | Nov 24, 2025 | Sell | $12.04 | 1,878 | $22,611.12 | 277,860 | |
| Dugel Pravin | OCUL | See Remarks | Nov 24, 2025 | Sell | $12.04 | 19,530 | $235,141.20 | 3,157,960 | |
| Kaiser Peter | OCUL | Chief Development Officer | Nov 24, 2025 | Sell | $12.02 | 3,007 | $36,144.14 | 191,433 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Nov 24, 2025 | Sell | $12.04 | 3,469 | $41,766.76 | 245,940 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
MT Newswires
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says
📉
AI Sentiment
Negative
3/10
Compare OCUL vs Leading Stocks
See how OCUL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.